


### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

### Listing of Claims:

1. (Currently Amended) A tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative having the general Formula I



**Formula I**

wherein

X is CH<sub>2</sub>, O or S;

R represents 1-3 substituents independently selected from H, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkyloxy and halogen;

R<sub>1</sub> is (C<sub>5-8</sub>)cycloalkyl;

R<sub>2</sub> is H or (C<sub>1-4</sub>)alkyl;

R<sub>3</sub>, R<sub>3</sub>', R<sub>4</sub>, R<sub>4</sub>', R<sub>5</sub>, R<sub>5</sub>' and R<sub>6</sub>' are independently hydrogen or (C<sub>1-4</sub>)alkyl, optionally substituted with (C<sub>1-4</sub>)alkyloxy, OH or halogen;

R<sub>6</sub> is hydrogen or (C<sub>1-4</sub>)alkyl, optionally substituted with (C<sub>1-4</sub>)alkyloxy, OH or halogen; or

R<sub>6</sub> forms together with R<sub>7</sub> a 4-7 membered saturated heterocyclic ring having only carbons as additional ring members; or

R<sub>7</sub> is H, (C<sub>1-4</sub>)alkyl or (C<sub>3-5</sub>)cycloalkyl, the alkyl groups being optionally substituted with OH, halogen or (C<sub>1-4</sub>)alkyloxy; or a pharmaceutically acceptable salt thereof.

2. (original) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein R is H and R<sub>1</sub> is cyclopentyl or cyclohexyl.

3. (Previously Presented) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein X is CH<sub>2</sub> or O.

4. (Currently Amended) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein R, R<sub>2</sub>, R<sub>3</sub>, R<sub>3</sub>', R<sub>4</sub>', R<sub>5</sub>, R<sub>5</sub>' and R<sub>6</sub>' are H; R<sub>4</sub>, R<sub>6</sub> and R<sub>7</sub> are independently H or (C<sub>1-4</sub>)alkyl; or R<sub>6</sub> forms together with R<sub>7</sub> a 5- or 6-membered saturated heterocyclic ring having only carbons as additional ring members and R<sub>4</sub> is H or (C<sub>1-4</sub>)alkyl.
5. (Cancelled)
6. (Previously Presented) A pharmaceutical composition comprising a tricyclic 1-[(indol-3-yl)-carbonyl]piperazine derivative of claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier therefor.
7. (Cancelled)
8. (Previously Presented) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 2, wherein X is CH<sub>2</sub> or O.
9. (Currently Amended) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 2, wherein R, R<sub>2</sub>, R<sub>3</sub>, R<sub>3</sub>', R<sub>4</sub>', R<sub>5</sub>, R<sub>5</sub>' and R<sub>6</sub>' are H; R<sub>4</sub>, R<sub>6</sub> and R<sub>7</sub> are independently H or (C<sub>1-4</sub>)alkyl; or R<sub>6</sub> forms together with R<sub>7</sub> a 5- or 6-membered saturated heterocyclic ring having only carbons as additional ring members and R<sub>4</sub> is H or (C<sub>1-4</sub>)alkyl.
10. (Currently Amended) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 3, wherein R, R<sub>2</sub>, R<sub>3</sub>, R<sub>3</sub>', R<sub>4</sub>', R<sub>5</sub>, R<sub>5</sub>' and R<sub>6</sub>' are H; R<sub>4</sub>, R<sub>6</sub> and R<sub>7</sub> are independently H or (C<sub>1-4</sub>)alkyl; or R<sub>6</sub> forms together with R<sub>7</sub> a 5- or 6-membered saturated heterocyclic ring having only carbons as additional ring members and R<sub>4</sub> is H or (C<sub>1-4</sub>)alkyl.
11. (Previously Presented) A method of treating pain in a patient in need of such treatment, comprising:  
administering an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
12. (Cancelled)